Omega-3 Fatty Acids
Omega-3 supplementation helps specific endpoints (triglycerides −20–33% at 4g/day, EPA-dominant depression SMD 0.40 per Mocking 2016) but Cochrane 2020 (Abdelhamid, n=162,796) found 'little or no effect' on all-cause mortality. AREDS2 confirmed null for AMD; AF risk rises +50% at 4g/day per the 2025 meta-analysis (34 trials, 114,326 participants).
Omega-3 Fatty Acids scored 6.8 / 10 (👍 Worth trying) on the BioHarmony scale as a Substance → Vitamin / Mineral / Nutrient.
What It Is
Type: Nutrient supplement (long-chain marine fatty acid blend; EPA + DHA from fish, krill, or algae). Current status: Tried and stopped. Omega-3 fatty acid supplements deliver eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), the two long-chain marine omega-3s that humans synthesize poorly from plant-derived ALA. Once absorbed, EPA and DHA incorporate into cell membrane phospholipids, compete with arachidonic acid for eicosanoid pathways, and serve as substrates for specialized pro-resolving mediators (resolvins, protectins, maresins) that actively terminate inflammation. The biomarker for tissue-level adequacy is the Omega-3 Index (% EPA+DHA in red blood cell membranes), with 8–12% as the cardioprotective target and ~5% as the Western average. The supplement category covers fish oil (most concentrated, multiple molecular forms), krill oil (phospholipid-bound, modest absorption edge at low doses but shellfish allergen), algae oil (DHA-dominant, cleanest source, vegan), and prescription icosapent ethyl (pure EPA at 4 g/day).
Terminology
- EPA: Eicosapentaenoic acid, a 20-carbon omega-3 fatty acid; primary substrate for E-series resolvins.
- DHA: Docosahexaenoic acid, a 22-carbon omega-3; structural component of neural membranes and substrate for D-series resolvins.
- Omega-3 Index: Percentage of EPA+DHA in red blood cell membranes. Western mean ~5%; target 8–12% for cardioprotection.
- SPM: Specialized pro-resolving mediators (resolvins, protectins, maresins) that actively terminate inflammation.
- TOTOX: Total oxidation value = 2×PV + AV. GOED freshness limit ≤26.
- PV: Peroxide Value, a marker of primary lipid oxidation (mEq O₂/kg). GOED limit ≤5.
- AV: p-Anisidine Value, marker of secondary oxidation. GOED limit ≤20.
- TG / EE / rTG: Triglyceride, ethyl ester, and re-esterified triglyceride forms of fish oil; differ in bioavailability and manufacturing.
- MACE: Major adverse cardiovascular events (composite of CV death, non-fatal MI, non-fatal stroke).
- NNT / NNH: Number needed to treat / harm.
- FADS1/FADS2: Fatty acid desaturase genes; polymorphisms affect ALA→EPA→DHA conversion efficiency.
- IFOS: International Fish Oil Standards, a 5-star third-party certification covering purity, oxidation, and label accuracy.
- REDUCE-IT: 2019 RCT of icosapent ethyl 4g/day vs mineral oil placebo, showing 25% MACE reduction.
- STRENGTH: 2020 RCT of EPA+DHA 4g/day vs corn oil placebo, terminated early for futility (null result).
- Vascepa / Lovaza: Prescription omega-3 brands; Vascepa is pure EPA EE, Lovaza is EPA+DHA EE.
How this score is calculated →
Upside (3.08 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 2.8 | 0.700 | |
| Breadth of Benefits | 15% | 3.5 | 0.525 | |
| Evidence Quality | 25% | 3.5 | 0.875 | |
| Speed of Onset | 10% | 2.5 | 0.250 | |
| Durability | 10% | 2.0 | 0.200 | |
| Bioindividuality Upside | 15% | 3.5 | 0.525 | |
| Total | 3.075 |
Upside Rationale
Efficacy (2.8/5.0) . Effect sizes are small-to-moderate and endpoint-specific. Triglyceride lowering is robust: 21–33% at 4 g/day (MARINE PMID 23992935) with linear dose-response. EPA-dominant formulations help depression (Mocking 2016, SMD 0.40, n=1,233 MDD patients). RA pain falls modestly (SMD −0.42 at ≥2.7 g/day, Lee 2022). NAFLD ultrasound improves (OR 3.83, 2024 20-RCT meta-analysis). But all-cause mortality is null in Cochrane 2020 (RR 0.97 across 162,796 participants), AMD progression is null (AREDS2, PMID 23644932), and cardiovascular outcomes are contested: REDUCE-IT positive but mineral-oil-placebo flawed; STRENGTH null with corn oil. At typical OTC doses (1–2 g/day), most effects are marginal.
Breadth of benefits (3.5/5.0) . Multi-system: cardiovascular (TG, BP, modest), inflammation (CRP −0.40, IL-6 −0.22), mood (EPA-dominant depression), joint (RA pain), liver (NAFLD fat reduction), skin (psoriasis PASI −1.58), pregnancy (42% preterm birth reduction <34 weeks per Cochrane). Touches half a dozen organ systems, but most effects are modest in magnitude rather than transformative.
Evidence quality (3.5/5.0) . Massive RCT base (500+ trials, multiple Cochrane reviews) but the headline findings are unfavorable: Cochrane 2020 (Abdelhamid, n=162,796) concluded "little or no effect" on all-cause mortality or stroke. AREDS2 confirmed AMD null. The single most-cited positive cardiovascular trial (REDUCE-IT, Bhatt 2019) used a mineral-oil placebo that elevated control-arm inflammatory markers, and the corn-oil-controlled replication (STRENGTH, Nicholls 2020) was null. Evidence Integrity Adjustment of −1.0 applied for industry-funded positive cardio trial plus failed independent replication. Strongest evidence is for triglyceride reduction, preterm-birth prevention, and EPA-dominant depression; weakest for the broad "foundational supplement" framing.
Speed of onset (2.5/5.0) . Triglycerides drop within 2 weeks at therapeutic dose, but most other endpoints take 4–16 weeks: inflammation at 4 weeks, depression at 4–8 weeks, Omega-3 Index plateau at 12–16 weeks. Not a felt-it-today intervention; structural changes accumulate over months.
Durability (2.0/5.0) . Effects are entirely supplementation-dependent. Omega-3 Index meaningfully declines within 6 weeks of stopping and washes out completely by 12 weeks. There is no permanent benefit and no protocol that can be cycled off without reversal.
Bioindividuality upside (3.5/5.0) . Strong responders are low-baseline Western adults (Omega-3 Index <5%), people with elevated TG, EPA-dominant depression cases, RA patients, and those with FADS1/FADS2 minor alleles that impair endogenous conversion. Weak responders include high-fish-eating populations (Japanese, Greenland Inuit) already at 9–11% baseline, ApoE4 carriers (blunted cognitive protection), and otherwise healthy biohackers eating fatty fish 2–3x weekly. Roughly half of supplementing Westerners get meaningful benefit; the rest are largely paying for placebo.
Per-Dimension Upside Rationales
Why each upside dimension scored what it did. Each rationale lead-sentence is the citable claim; the rest is the supporting evidence.
Efficacy
2.8 / 5Effect sizes are small-to-moderate and endpoint-specific. Triglyceride lowering is robust at 21–33% at 4g/day (MARINE PMID 23992935) with linear dose-response. EPA-dominant formulations help depression (Mocking 2016, SMD 0.40, n=1,233 MDD patients). RA pain falls modestly (SMD −0.42 at ≥2.7g/day, Lee 2022). NAFLD ultrasound improves (OR 3.83, 2024 20-RCT meta-analysis). But all-cause mortality is null in Cochrane 2020 (RR 0.97 across 162,796 participants), AMD progression null (AREDS2), and cardiovascular outcomes contested: REDUCE-IT positive but mineral-oil-placebo flawed; STRENGTH null with corn oil. At typical OTC doses (1–2g/day), most effects are marginal.
Breadth of Benefits
3.5 / 5Multi-system reach across cardiovascular (TG, BP, modest), inflammation (CRP −0.40, IL-6 −0.22 per Kaviani 2022), mood (EPA-dominant depression), joint (RA pain), liver (NAFLD fat reduction), skin (psoriasis PASI −1.58), and pregnancy (42% preterm birth reduction <34 weeks per Cochrane Abdelhamid 2020). Touches half a dozen organ systems but most effects are modest in magnitude rather than transformative. Earns the breadth credit, falls short of the rare interventions that produce large effects across multiple systems simultaneously.
Evidence Quality
3.5 / 5Massive RCT base of 500+ trials and multiple Cochrane reviews, but the headline findings are unfavorable. Cochrane 2020 (Abdelhamid, n=162,796) concluded "little or no effect" on all-cause mortality or stroke. AREDS2 confirmed AMD null. The most-cited positive cardiovascular trial REDUCE-IT (Bhatt 2019) used a mineral-oil placebo that elevated control-arm inflammatory markers, and the corn-oil-controlled replication STRENGTH (Nicholls 2020) was null. Evidence Integrity Adjustment of −1.0 applied for industry-funded positive cardio trial plus failed independent replication. Strongest evidence is for triglyceride reduction, preterm-birth prevention, and EPA-dominant depression.
Speed of Onset
2.5 / 5Triglycerides drop within 2 weeks at therapeutic dose, but most other endpoints take 4–16 weeks: anti-inflammatory effects at 4 weeks, depression response at 4–8 weeks, Omega-3 Index plateau at 12–16 weeks (RBC turnover ~120 days). Not a felt-it-today intervention. Structural changes accumulate over months as EPA and DHA incorporate into cell membrane phospholipids. Users expecting acute effects will conclude it does nothing; users committed to a 12-week minimum trial give the benefits time to manifest.
Durability
2.0 / 5Effects are entirely supplementation-dependent. Omega-3 Index meaningfully declines within 6 weeks of stopping and washes out completely by 12 weeks. There is no permanent benefit and no protocol that can be cycled off without reversal. Unlike a strength-training adaptation or a vitamin D loading dose, omega-3 must be continuously replenished from diet or supplement. The only path to durable benefit is a permanent dietary shift toward fatty fish (sardines, mackerel, wild salmon) consumed 2–3x weekly, which delivers EPA+DHA in a food matrix.
Bioindividuality Upside
3.5 / 5Strong responders are low-baseline Western adults (Omega-3 Index <5%), people with elevated triglycerides, EPA-dominant depression cases, RA patients, and those with FADS1/FADS2 minor alleles that impair endogenous conversion of plant ALA to EPA/DHA. Weak responders include high-fish-eating populations (Japanese, Greenland Inuit) already at 9–11% baseline, ApoE4 carriers (blunted cognitive protection), and otherwise healthy biohackers eating fatty fish 2–3x weekly. Roughly half of supplementing Westerners get meaningful benefit; the rest are largely paying for placebo. Test the Omega-3 Index before deciding.
Downside (2.31 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 2.0 | 0.600 | |
| Side Effect Profile | 15% | 2.5 | 0.375 | |
| Financial Cost | 5% | 2.0 | 0.100 | |
| Time/Effort Burden | 5% | 1.0 | 0.050 | |
| Opportunity Cost | 5% | 2.5 | 0.125 | |
| Dependency / Withdrawal | 15% | 1.5 | 0.225 | |
| Reversibility | 25% | 1.0 | 0.250 | |
| Total | 1.725 | |||
| Harm subtotal × 1.4 | 2.030 | |||
| Opportunity subtotal × 1.0 | 0.275 | |||
| Combined downside | 2.305 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.965 |
Downside Rationale
Safety risk (2.0/5.0) . At supplemental doses (1–2 g/day), the safety profile is benign: mild bleeding tendency, no AF signal in VITAL or ASCEND. At therapeutic doses (≥3 g/day), atrial fibrillation risk becomes intrinsic and dose-dependent: REDUCE-IT 5.3% vs 3.9% (HR 1.69), Gencer 2021 meta-analysis OR 1.25, 2025 update +50% AF at 4 g/day. AF can cause cardioembolic stroke; this qualifies for the catastrophic risk floor consideration at high dose only. Krill oil carries an absolute shellfish-allergy contraindication (anaphylaxis documented); fish oil for fish-allergic individuals likewise. Score reflects typical OTC consumer use; high-dose users should mentally add 1.5–2.0 points.
Side effect profile (2.5/5.0) . Fishy burps in 10–30% (most common, mitigable by freezing capsules, enteric coating, or splitting doses with food). Nausea 5–8%, dyspepsia 4–7%, diarrhea 3–6%. LDL-C rises ~5–10% with high-dose DHA-containing products in hypertriglyceridemic patients; pure EPA (Vascepa) avoids this. AEs are common but mild and rarely treatment-limiting at supplemental doses.
Financial cost (2.0/5.0) . IFOS-certified fish oil $20–40/mo, premium rTG/krill $40–80/mo, Vascepa generic $60–300/mo. Affordable for most. Quality cost premium is real: cheap commodity brands frequently fail oxidation testing (25–83% rancid per Ritter 2013, Consumer Lab), so the practical floor for a quality product is ~$25/mo.
Time/effort burden (1.0/5.0) . Capsules with the largest fatty meal of the day. Trivial.
Opportunity cost (2.5/5.0) . Modest. The "just eat fatty fish" critique has merit: 2–3 servings of sardines/mackerel/wild salmon weekly delivers EPA+DHA in a food matrix with selenium, protein, and (in salmon) astaxanthin. Supplementation can crowd out fish-eating habits without delivering equivalent benefit. Rancid product is net-negative (animal data show oxidized fish oil promotes hepatic lipid accumulation). For some users the dollar spent on omega-3 would do more in a different category (vitamin D, magnesium, sleep optimization).
Dependency / withdrawal (1.5/5.0) . No physiological dependency. No rebound phenomenon. Effects fade gradually as the Omega-3 Index normalizes over 6–12 weeks. The "dependency" is functional only: if you want continued benefit, you must continue taking it.
Reversibility (1.0/5.0) . Fully reversible. Stop the supplement and tissue levels return to baseline within 12 weeks. No permanent changes.
Per-Dimension Downside Rationales
Why each downside dimension scored what it did. Each rationale lead-sentence is the citable claim; the rest is the supporting evidence.
Safety Risk
2.0 / 5At supplemental doses (1–2g/day), the safety profile is benign: mild bleeding tendency, no atrial fibrillation signal in VITAL or ASCEND. At therapeutic doses (≥3g/day), AF risk becomes intrinsic and dose-dependent: REDUCE-IT 5.3% vs 3.9% (HR 1.69), Gencer 2021 meta-analysis OR 1.25, 2025 update +50% AF at 4g/day across 34 trials and 114,326 participants. AF can cause cardioembolic stroke, qualifying for the catastrophic risk floor consideration at high dose only. Krill oil carries an absolute shellfish-allergy contraindication (anaphylaxis documented); fish oil likewise for fish-allergic individuals. Score reflects typical OTC consumer use; high-dose users should mentally add 1.5–2.0 points.
Side Effect Profile
2.5 / 5Fishy burps in 10–30% are the most common AE (mitigable by freezing capsules, enteric coating, or splitting doses with food). Nausea affects 5–8%, dyspepsia 4–7%, diarrhea 3–6%. LDL-C rises ~5–10% with high-dose DHA-containing products in hypertriglyceridemic patients; pure EPA (Vascepa/icosapent ethyl) avoids this. AEs are common but mild and rarely treatment-limiting at supplemental doses. Most discontinuations happen for the burps, not for medical reasons. Switching to a higher-quality TG or rTG form usually resolves GI complaints.
Financial Cost
2.0 / 5IFOS-certified fish oil $20–40/mo, premium rTG and krill $40–80/mo, Vascepa generic $60–300/mo depending on insurance and pharmacy. Affordable for most readers. The quality cost premium is real: cheap commodity brands frequently fail oxidation testing (25–83% rancid per Ritter 2013 + ConsumerLab audits), so the practical floor for a quality product is roughly $25/mo. Buying the cheapest option on Amazon is functionally a placebo at best, mildly harmful at worst. Pay the quality premium or do not supplement.
Time/Effort Burden
1.0 / 5Capsules with the largest fatty meal of the day. Trivial. No timing rituals, no fasting requirements, no cycling protocol. Total daily compliance burden is roughly 30 seconds. Unlike interventions that require workout windows, sleep hygiene, or restricted feeding, omega-3 supplementation has effectively zero behavioral cost. That makes it one of the easier interventions to actually sustain at the multi-month timeframe required for the benefits to manifest.
Opportunity Cost
2.5 / 5Modest. The "just eat fatty fish" critique has merit: 2–3 servings of sardines, mackerel, or wild salmon weekly delivers EPA+DHA in a food matrix with selenium, protein, and (in salmon) astaxanthin. Supplementation can crowd out fish-eating habits without delivering equivalent benefit. Rancid product is net-negative (animal data show oxidized fish oil promotes hepatic lipid accumulation). For some users the dollar spent on omega-3 would do more in a different category: vitamin D for the Omega-3 Index <5% group, magnesium for sleep, glycine for HRV.
Dependency / Withdrawal
1.5 / 5No physiological dependency. No rebound phenomenon. Effects fade gradually as the Omega-3 Index normalizes over 6–12 weeks rather than the abrupt withdrawal you see with stimulants, sleep aids, or hormone replacement. The "dependency" is functional only: if you want continued benefit, you must continue taking it (or switch to dietary fish). This is the same kind of dependency you have on eating vegetables: descriptive, not addictive. Score reflects the functional-not-addictive distinction in the v0.5 dependency rules.
Reversibility
1.0 / 5Fully reversible. Stop the supplement and red-blood-cell membrane composition returns to dietary baseline within 12 weeks (RBC turnover ~120 days). No permanent changes. No tissue accumulation that persists beyond washout. No epigenetic imprint, no irreversible enzyme induction, no anatomic remodeling. This is the cleanest possible reversibility profile: a stop-and-revert intervention with effectively no commitment beyond the time horizon of the next quarterly Omega-3 Index test.
Verdict
✅ Best for: People with documented low Omega-3 Index (<5%, confirmed via OmegaQuant), elevated triglycerides (>150 mg/dL, especially >500), EPA-dominant adjunct for unipolar depression (≥1 g EPA/day, EPA fraction >60%), pregnancy and lactation (DHA via algae for purity), rheumatoid arthritis pain reduction (≥2.7 g EPA+DHA), NAFLD (≥2 g/day), and FADS1/FADS2 minor-allele carriers with impaired endogenous conversion. Vegans should default to a Nannochloropsis-based algae product to get meaningful EPA, not just DHA.
❌ Avoid if: You eat fatty fish 2–3x weekly already (high baseline, marginal supplementation benefit), have existing atrial fibrillation or significant AF risk factors (limit to ≤1 g/day or skip), are shellfish-allergic (krill is a crustacean, anaphylaxis risk), are on warfarin or dual antiplatelet therapy without monitoring, or are tempted to buy an uncertified bargain product (rancid oil is net-negative; IFOS or NSF certification is the floor). Skip entirely if your fish-oil purchase is a substitute for fixing diet.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
| Use Case | Score | Summary |
|---|---|---|
| 👍 Cardiovascular Primary | 6.0 | Dose-dependent. REDUCE-IT (Bhatt 2019, NNT 21 at 4g pure EPA) is real but contested by mineral oil placebo. STRENGTH (Nicholls 2020, corn oil placebo) was null. Cochrane 2020 (Abdelhamid): RR 0.92 for CV mortality, no effect on stroke. Modest at best at OTC doses. |
| 👍 Anti-Inflammatory Primary | 6.0 | Kaviani 2022 umbrella meta-analysis (PMID 35914448): CRP ES −0.40, IL-6 ES −0.22. Real but modest, requires ≥2g/day for ≥8 weeks. |
| 👍 Metabolic Health Primary | 6.0 | Strong for TG: 21–33% reduction at 4g/day (MARINE PMID 23992935). Null for fasting glucose and insulin sensitivity in meta-analyses. |
| 👍 Depression Primary | 6.5 | Mocking 2016 meta-analysis (PMID 26978738): SMD 0.40 for EPA-dominant formulations in MDD. Cochrane 2021 (Appleton, PMID 33769549) more skeptical: 'uncertain effect' overall, EPA subgroup effect remains. |
| 💪 Prenatal (Maternal & Fetal Outcomes) Primary | 7.0 | Cochrane: 42% reduction in preterm birth <34 weeks. WHO/ACOG recommend >=200mg DHA/day for fetal neurodevelopment. Algae oil preferred for purity. STRONG signal in pregnant population only. |
| 👍 Bone / Joint Health | 6.0 | RA pain SMD −0.42 (Lee 2022, PMID 35900212); NSAID-sparing demonstrated. Strongest signal at ≥2.7g EPA+DHA for ≥12 weeks. |
| 👍 Liver / Detoxification | 6.0 | NAFLD: OR 3.83 for ultrasound-based fat reduction (2024 meta-analysis, 20 RCTs). ALT/AST consistently lower. MRI-based quantification less convincing. |
| ⚖️ Mood / Emotional Regulation | 5.5 | Adjunctive benefit for low-grade mood issues; effect modest in non-clinical populations. |
| ⚖️ Chronic Pain Management | 5.0 | Same RA evidence applies; less data for non-rheumatic chronic pain conditions. |
| ⚖️ Pediatric Use | 5.0 | DHA for infant neurodevelopment well-established; ADHD modest (SMD −0.16 short-term, −0.35 at ≥4mo per Chang 2023). |
| ⚖️ Geriatric / Aging Population | 5.0 | Strongest signal in elderly with low baseline Omega-3 Index. Caution: AF risk dose-dependent, especially in elderly. |
| ○ Cognition / Focus | 4.5 | VITAL cognition substudy (Kang 2022) null for general population. Modest signal in low-fish-intake or mild cognitive impairment subgroups (MIDAS, DHA 900mg). |
| ○ Memory | 4.5 | MIDAS (Yurko-Mauro 2010): improved paired associate learning in age-associated memory impairment, not established Alzheimer's. |
| ○ Recovery / Repair | 4.5 | DOMS reduction in some RCTs (ibuprofen-comparable); MPS augmentation (Smith 2011) not consistently replicated. |
| ○ Healthspan | 4.5 | Same as longevity. Modest plausible contribution via reduced inflammation. |
| ○ Anxiety | 4.0 | Su 2018 meta-analysis showed small effect (SMD 0.37) but heterogeneity high. Less robust than depression signal. |
| ○ Neuroprotection | 4.0 | Mechanistically plausible (DHA brain incorporation), but no convincing prevention RCTs for dementia. |
| ○ Injury Recovery | 4.0 | Anti-inflammatory plausible mechanism; specific evidence thin for orthopedic injury. |
| ○ Longevity / Lifespan | 4.0 | All-cause mortality null in Cochrane 2020 and 19-RCT 2023 meta-analysis. Observational Omega-3 Index → mortality association is suggestive but unproven causal. |
| ○ Skin / Beauty | 4.0 | Atopic dermatitis and psoriasis modest improvement (PASI −1.58 in some meta-analyses); evidence heterogeneous. |
| ○ Fertility (Male) | 4.0 | Sperm motility and morphology improvement in 2019 meta-analysis (Hosseini 2019). Modest, dose-dependent. |
| ○ Traumatic Brain Injury | 4.0 | Mechanistic case for DHA in brain repair; small trials suggestive, not yet practice-changing. |
| ○ Antioxidant / Oxidative Stress | 3.5 | PUFA itself is OXIDATION-PRONE; net antioxidant effect via inflammation reduction, not direct radical scavenging. Astaxanthin pairing common. |
| ○ Immune Function | 3.5 | Resolvins/protectins modulate immune resolution; clinical immune outcome data limited. |
| ○ HRV / Vagal Tone / Autonomic Balance | 3.5 | Some HRV improvement in CV trials; modest signal. |
| ○ Neuroplasticity | 3.5 | DHA is structural for neuronal membranes; mechanistic plausibility, limited clinical proof. |
| ○ Muscle Growth / Hypertrophy | 3.0 | Smith 2011 MPS data not replicated in 2024 meta-analysis (PMID 38777807); no consistent hypertrophy signal. |
| ○ Endurance / Cardio | 3.0 | Mixed; small VO2max effects in some trials, null in most. |
| ○ Strength / Power | 3.0 | No consistent effect on force output or 1RM. |
| ○ VO2 Max | 3.0 | Inconsistent across studies; not a primary effect. |
| ○ Acute Pain Relief | 3.0 | Slow onset (weeks); not useful for acute pain. |
| ○ Mitochondrial | 3.0 | PPARα activation modulates fatty acid oxidation; no direct mitochondrial endpoint data. |
| ○ Stress / Resilience | 3.0 | Indirect via mood/inflammation; no direct stress RCTs. |
| ○ Nerve Regeneration | 3.0 | Animal models supportive; thin human clinical data. |
| ○ Respiratory | 3.0 | Asthma adjunct mixed evidence; no robust signal. |
| ○ Fertility (Female) | 3.0 | Limited direct fertility data; pregnancy outcomes evidence stronger than pre-conception fertility. |
Frequently Asked Questions
Is omega-3 supplementation actually worth it?
Conditional yes. The Cochrane 2020 review (Abdelhamid, n=162,796) found 'little or no effect' on all-cause mortality or cardiovascular events at typical doses. But specific endpoints respond strongly: triglycerides drop 21–33% at 4 g/day (MARINE), preterm birth falls 42% before 34 weeks (Cochrane), and EPA-dominant formulations help depression (Mocking 2016, SMD 0.40). For people with low Omega-3 Index (<5%), elevated TG, or mood/inflammation issues, the case is stronger. For healthy biohackers eating fatty fish 2–3x weekly, marginal benefit.
How much omega-3 should I take per day?
Goal-dependent. 1 g EPA+DHA/day is the minimum for general health (insufficient to push Omega-3 Index above 8% in most). 2–4 g/day for inflammation, mood (EPA-dominant), or NAFLD. 4 g/day pure EPA (Vascepa) for cardiovascular risk reduction in qualifying patients. The sophisticated approach: test Omega-3 Index via OmegaQuant ($50–70), titrate to 8–12%, retest at 3 months. Peter Attia takes ~2.5 g EPA + 1 g DHA daily; Rhonda Patrick reduced to 2 g/day after testing showed her index at 16%.
What's the difference between fish oil, krill oil, and algae oil?
Fish oil delivers the most EPA+DHA per dollar; rTG (re-esterified triglyceride) form is the bioavailability winner. Krill oil binds EPA/DHA to phospholipids . Modest absorption edge at <2 g doses (Ulven 2011, ~13% advantage), cost-prohibitive at therapeutic doses, and absolute contraindication in shellfish allergy. Algae oil is the cleanest source (no PCBs, mercury, allergens) and the only vegan option, but most products are DHA-dominant; DHA-to-EPA retroconversion is only 0–9% (Arterburn 2006), so vegans seeking EPA effects need explicitly EPA-containing algae products like Nannochloropsis-based formulations.
Does omega-3 cause atrial fibrillation?
Dose-dependent yes at therapeutic doses. The 2025 meta-analysis (34 trials, 114,326 participants) confirmed +12% AF risk at 1 g/day and +50% at 1800–4000 mg/day. REDUCE-IT showed 5.3% vs 3.9% AF (HR 1.69) at 4 g pure EPA; STRENGTH replicated the signal at 2.2% vs 1.3%. Mechanism: high-dose EPA shortens atrial effective refractory period. Supplemental doses (1–2 g/day) show minimal signal in VITAL and ASCEND. People with existing AF or AF risk factors should not exceed 1 g/day without cardiology supervision.
Is most commercial fish oil rancid?
Yes, alarmingly often. Independent testing has found 25–83% of commercial fish oils exceed GOED TOTOX limits (≤26) at point of sale: Ritter 2013 in New Zealand (83%), Consumer Lab 2020–2022 (multiple brands >40), LabDoor 2019 (~30%). Oxidized EPA/DHA loses biological activity and may cause net harm in animal models (Ottestad 2012). Mitigation: buy IFOS 5-star certified brands (Sports Research, Carlson, Bare Biology, Wiley's Finest), check manufacture date, refrigerate after opening. Home check: freeze a softgel and bite it . Fresh oil smells mildly oceanic, rancid oil smells like paint thinner.
Who should NOT take omega-3 supplements?
Absolute contraindications: fish allergy (avoid fish oil; algae is alternative), shellfish allergy (avoid krill oil; krill IS a crustacean and anaphylaxis is documented), serious bleeding disorders, existing AF for high-dose use. Relative caution: anticoagulant therapy (warfarin INR may rise; limit to ≤2 g/day without supervision), scheduled surgery within 7–14 days (conventional discontinuation guidance, though Siegal 2012 suggests bleeding risk lower than feared at <3 g/day), advanced liver disease, type 2 diabetes with marginal HbA1c (Lovaza specifically may worsen ~0.2%; Vascepa does not).
What's the deal with REDUCE-IT and the mineral oil placebo controversy?
REDUCE-IT (Bhatt 2019, NEJM, n=8,179) showed 25% MACE reduction with 4 g/day icosapent ethyl. The placebo was mineral oil . Not inert. Placebo-arm LDL rose 11%, hsCRP rose 15%, ApoB rose 9% over the trial. Critics including Steve Nissen (PMID 32459343) argue this artificially inflated the apparent benefit. STRENGTH (Nicholls 2020, n=13,078, corn oil placebo) was null. Hoogeveen & Ballantyne 2022 meta-analysis: when only neutral-placebo trials are pooled, CV benefit disappears. Bottom line: REDUCE-IT's benefit is probably real but likely overestimated by 30–50%; AF harm signal is real and not placebo-dependent.
How long until I notice an effect from omega-3?
Endpoint-dependent. Triglycerides drop measurably within 2 weeks at 4 g/day. CRP/IL-6 fall by 4 weeks. Depression response lags 4–8 weeks (typical antidepressant timeline). Omega-3 Index reaches steady state at 12–16 weeks given RBC turnover (~120 days). After stopping, levels meaningfully decline over 6 weeks and washout completely by ~12 weeks. There is no acute effect . Omega-3 is a sustained, structural intervention, not a felt-it-today supplement. If you want to verify the dose is actually working, OmegaQuant testing at baseline and again at 16 weeks is the gold standard.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimension Changes | New Score |
|---|---|---|
| New head-to-head Vascepa vs. neutral-placebo RCT replicates 25% MACE reduction | Evidence 3.5→4.5, Efficacy 2.8→3.5 | 7.4 / 10 💪 Strong recommend |
| Confirmation that REDUCE-IT was placebo-artifact and high-dose CV benefit is null | Evidence 3.5→3.0, Efficacy 2.8→2.3, Safety 2.0→2.5 | 6.0 / 10 👍 Worth trying |
| Industry adopts mandatory TOTOX disclosure + IFOS certification standardizes quality across the category | Side Effects 2.5→2.0, Opportunity Cost 2.5→2.0 | 7.0 / 10 💪 Strong recommend |
| Algae oil reaches EPA parity with fish oil at competitive price (cleanest source dominates) | Safety 2.0→1.5, Side Effects 2.5→2.0 | 7.1 / 10 💪 Strong recommend |
| Large RCT confirms AF risk is significant at 1–2 g/day, not just at 4 g/day | Safety 2.0→3.0, Bioindividuality 3.5→3.0 | 5.7 / 10 ⚖️ Neutral |
Key Evidence Sources
- Cochrane 2020 . Abdelhamid et al, Omega-3 Fatty Acids for the Primary and Secondary Prevention of Cardiovascular Disease. n=162,796. RR 0.92 for CV mortality; null for stroke and all-cause mortality. The largest meta-analysis to date . Major reason omega-3 is "Worth trying" not "Strongly recommended" for general cardiovascular prevention.
- REDUCE-IT (Bhatt et al, NEJM 2019) . Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. NNT 21 at 4g/day pure EPA (icosapent ethyl). Real CV event reduction but contested by mineral oil placebo arm.
- STRENGTH (Nicholls et al, JAMA 2020) . Effect of High-Dose Omega-3 on Major Adverse Cardiovascular Events. Null result with corn oil placebo. Counter-evidence to REDUCE-IT; suggests the REDUCE-IT signal may have been driven by mineral oil placebo harm rather than EPA benefit.
- MARINE Trial . Bays et al, Eicosapentaenoic Acid Ethyl Ester on Triglyceride Levels. PMID 23992935. 21–33% triglyceride reduction at 4g/day. Strongest single endpoint signal for omega-3 across the literature.
- Mocking et al 2016 . Meta-analysis of Omega-3 Polyunsaturated Fatty Acid Supplementation in Major Depressive Disorder. PMID 26978738. SMD 0.40 for EPA-dominant formulations in MDD. The depression-subgroup signal that earns omega-3 a 6.5 prenatal-aside.
- Cochrane 2021 . Appleton et al, Omega-3 Fatty Acids for Depression in Adults. PMID 33769549. More skeptical "uncertain effect" overall but EPA subgroup effect remains. Cited as the conservative counterpoint to Mocking 2016.
- Kaviani et al 2022 . Umbrella Meta-Analysis of Omega-3 Effects on Inflammation Markers. PMID 35914448. CRP effect size −0.40, IL-6 effect size −0.22. Modest but real anti-inflammatory signal at ≥2g/day for ≥8 weeks.
- Lee et al 2022 . Omega-3 in Rheumatoid Arthritis Pain. PMID 35900212. RA pain SMD −0.42; NSAID-sparing effect demonstrated. Strongest signal at ≥2.7g EPA+DHA for ≥12 weeks.
- VITAL Cognition Substudy . Kang et al 2022. Null for general-population cognitive decline. Source of "do NOT take this for cognition unless you have a measured low Omega-3 Index" caveat.
- MIDAS . Yurko-Mauro et al 2010, DHA and Age-Associated Memory Impairment. DHA 900mg improved paired associate learning in age-associated memory impairment (NOT established Alzheimer's). Carefully scoped finding.
- Chang et al 2023 . Omega-3 in Pediatric ADHD. SMD −0.16 short-term, −0.35 at ≥4 months. Modest pediatric signal; not a substitute for first-line treatment.
- Hosseini et al 2019 . Omega-3 and Male Sperm Parameters. Sperm motility and morphology improvement in meta-analysis. Modest, dose-dependent.
- WHO/ACOG Joint Recommendation . Prenatal DHA for Reduction of Preterm Birth. ≥200mg DHA/day in pregnancy. Underpins the prenatal use case 7.0 score.
- 2025 AF-Risk Meta-Analysis . Omega-3 Atrial Fibrillation Risk. 34 trials, 114,326 participants. AF risk +50% at 4g/day vs lower doses. Reason for the safety/dependency penalty in the BioHarmony score.
Other interventions for Cardiovascular
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. 5.0 is neutral (benefits and risks balance). Above 5 = benefits outweigh risks; below 5 = risks outweigh benefits.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 3.075 − 2.305 = 0.770
EV ranges from −5 to +5. Adding 7 shifts to 2–12, dividing by 12 normalizes to 0–1, then ×10 gives the 0–10 score.
Score = ((0.770 + 7) / 12) × 10 = 6.8 / 10
